FXR/TGR5 Dual Agonist Prevents Progression of Nephropathy in Diabetes and Obesity
Xiaoxin X. Wang(Beijing Obstetrics and Gynecology Hospital), Moshe Levi(Georgetown University), Enrico Gratton(University of California, Irvine), Komuraiah Myakala(Georgetown University), Suman Ranjit(Georgetown University), Kammi Henriksen(University of Chicago), Avi Z. Rosenberg(Johns Hopkins University), David J. Orlicky(University of Colorado Anschutz Medical Campus), Jeffrey B. Kopp(National Institute of Diabetes and Digestive and Kidney Diseases), Jonathan Levi(National Institutes of Health), Gabriel García(University of Colorado Denver), Yuhuan Luo(University of Colorado Anschutz Medical Campus), Evgenia Dobrinskikh(University of Colorado Anschutz Medical Campus), Luciano Adorini(Intercept Pharmaceuticals (United States)), Michal Herman‐Edelstein(Rabin Medical Center), Mark Pruzanski(University of Padua), Kristopher W. Krausz(National Institutes of Health), Amanda Field(Children's National), Frank J. Gonzalez(National Cancer Institute), Yingqiong Peng(University of Colorado Anschutz Medical Campus), Dong Wang(University of Colorado Denver), Ashley Hill(Children's National), Scott Lucia(University of Colorado Anschutz Medical Campus), Liru Qiu(University of Colorado Anschutz Medical Campus), Tao Jiang(Third Affiliated Hospital of Southern Medical University), Vivette D. D’Agati(Columbia University), Alexander Dvornikov(Fluor (United States)), Cen Xie(Nanjing University of Chinese Medicine)
Cited by 222
Related Papers
Triglycerides and Cardiovascular Disease
|Circulation|2011|1.9k
Lipid Rafts Reconstituted in Model Membranes
|Biophysical Journal|2001|1.4k
The Phasor Approach to Fluorescence Lifetime Imaging Analysis
|Biophysical Journal|2007|1.2k
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
|New England Journal of Medicine|2016|1.1k